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More people live with HIV in South Africa (SA) than any other country 
in the world. In 2010 approximately 68% of all people infected with 
HIV resided in sub-Saharan Africa, which has only 12% of the world’s 
population. The roll-out of antiretroviral therapy (ART) commenced 
in the public sector in SA in 2004 and has increased dramatically since 
then. According to UNAIDS World AIDS Day Report 2011, 40 - 59% 
of eligible South Africans were receiving ART by the end of 2010, 
which is the largest comprehensive ART programme in the world.1 
Although widespread access to ART has improved quality of life and 
reduced AIDS-related deaths and HIV transmission, the challenges to 
the healthcare sector remain considerable. 
Cytopenias
Cytopenias are one of the most common complications of HIV 
and may be broadly classified as being due either to a bone marrow 
production defect or to increased peripheral loss or destruction of 
blood cells. Anaemia is the most common cytopenia and occurs in 
up to 95% of HIV patients during their disease course.2 There are a 
multitude of possible causes of anaemia in HIV (Table 1). 
The main mechanism for anaemia of chronic disease is perturbed 
bone marrow cytokine homeostasis. HIV is cytotoxic to T-helper 
lymphocytes, which in turn leads to dysregulation of B cells and 
altered release of cytokines. HIV-infected T cells directly suppress 
growth of bone marrow progenitors, thus suppressing haemopoiesis. 
CD4, the cell-surface receptor target of HIV, is carried by T-helper 
lymphocytes, monocytes and microvascular endothelial cells which 
are prevalent in marrow. The infection of monocytes in the marrow 
further alters release of cytokines, which indirectly suppress the 
capacity for haemopoietic progenitor cells to adequately respond to 
anaemia and other peripheral cytopenias. This explains why in most 
patients with advanced HIV pancytopenia is the rule.3
Cytopenias due to drug therapy (Table 2) add to the diagnostic 
challenge in HIV patients with cytopenias and may require drug 
cessation. Culprits include zidovudine (AZT) and stavudine (d4T), 
co-trimoxazole (Bactrim) and the antituberculosis drugs isoniazid, 
rifampicin and rifabutin.4 In patients presenting with anaemia, 
baseline haematinic studies including serum ferritin, serum B12 
and red-cell folate are essential, and significant deficiencies should 
routinely be excluded. Although iron deficiency typically causes 
a microcytic anaemia and B12 and folate deficiency a macrocytic 
anaemia, this distinction often becomes blurred in HIV patients who 
typically become macrocytic while receiving ART. Highly active ART 
(HAART) is an important intervention in cytopenic HIV patients, as 
it alleviates the cytokine disturbances. However, if patients develop a 
new cytopenia while taking HAART, then a drug-induced cytopenia 
must be considered and a change of HAART regimen may be 
required.
Infections
Opportunistic infections such as Mycobacterium tuberculosis, M. 
avium complex (MAC) and Cryptococcus neoformans can cause 
cytopenias by infiltrating the bone marrow and causing reactive 
granuloma formation (Fig. 1). A bone marrow biopsy can provide 
a morphological diagnosis within a few days. A study by the 
University of Cape Town (UCT) haematology department at Groote 
Schuur Hospital (GSH), which included 147 patients, showed the 
high diagnostic utility of a bone marrow biopsy in HIV patients 
presenting with unexplained cytopenias and/or fever.5 A bone 
marrow biopsy gave an overall diagnostic yield of 47% with a unique 
diagnosis, defined as a diagnosis not made by any other modality 
and which resulted in a change in patient management, made in 
33% of patients. Mycolytic cultures of the blood and bone marrow 
were important adjuncts which added to the high diagnostic yield 
of tuberculosis (TB) in this study. However, cultures have a much 
longer turnaround time than morphology. Notably, patients in the 
study group generally had advanced HIV disease (the median CD4 
count was 73 x 106/l; with 43% of cases having CD4 <50 x 106/l), 
which probably contributed towards the high diagnostic yield. 
The most common unique diagnoses made were disseminated 
mycobacterial infection and immune thrombocytopenic purpura 
(ITP) (14% each), followed by malignancies (4%). The unexpected 
malignancies found on bone marrow examination included 4 
cases of primary bone marrow Hodgkin lymphoma (HL) and 
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1 case of non-Hodgkin lymphoma (NHL). In the marrows that 
were not specific diagnostically, morphological dysplasia of one 
or more cell lines was a frequent finding. HIV dysplasia, which is 
a well-recognised entity, is non-clonal and must be distinguished 
from the preleukaemic myelodysplastic syndrome, although the 
morphological features are often indistinguishable. Morphological 
features of HIV dysplasia become more marked as the disease 
progresses.
Immunosuppressed HIV patients are predisposed to parvovirus 
B19 infection, which should be suspected in all cases of isolated 
severe anaemia, usually with preserved platelet and white cell 
counts. Parvovirus B19 is a DNA virus which is usually acquired 
through the respiratory tract, and infects red-cell precursors in 
the bone marrow. The virus then replicates and lyses these red-cell 
precursors, leading to a marked reduction in erythroid activity in 
the marrow. There is an absent or very low reticulocyte response. 
There are characteristic morphological features on the bone marrow 
biopsy such as red-cell maturation arrest and giant pronormoblasts, 
but the bone marrow biopsy is not required for diagnosis. Polymerase 
chain reaction (PCR) is the diagnostic test of choice. Serology is 
often unhelpful because during advanced HIV infection, patients 
are unable to mount a serological response. Management includes 
HAART, red-cell transfusions and intravenous immunoglobulin 
therapy, if available.6 
Immune thrombocytopenic purpura
ITP occurs in up to 30% of HIV patients and is the most 
common cause of thrombocytopenia in HIV. Although the clinical 
presentation is similar to non-HIV-associated ITP, the mechanism 
is unique and thought to be due to an HIV-induced auto-antibody 
generated against an amino-acid sequence within the platelet 
surface glycoprotein IIIa.2 Many patients present with ITP as the 
first manifestation of HIV, although it can occur in both early and 
Fig. 1. An HIV-positive male patient had a bone marrow biopsy performed for 
the investigation of bicytopenia and fever. The CD4 count was 10 x 106/l. (A) 
The trephine biopsy showed non-caseating granulomata with multinucleated 
giant cells (black arrow). (B) The Ziehl-Neelsen (ZN) stain demonstrated 
numerous acid-fast bacilli packing the multinucleate giant cells and histiocytes. 
These morphological features are characteristic for Mycobacterium avium 
complex which was confirmed on mycolytic blood cultures.
Table 1. Approach to anaemia in HIV
Reduced red cell production Increased red cell loss
Related to HIV
Infection
HIV itself, mycobacteriae, parvovirus, fungi
Malignancy
High-grade NHL, HL
Drugs
Zidovudine, co-trimoxazole, isoniazid 
Anaemia of chronic disease
Related to HIV
Haemolysis
TTP, autoimmune haemolytic anaemia 
Blood loss
Gastrointestinal, high-grade NHL, Kaposi sarcoma, infection (CMV, 
Candida) 
Hypersplenism
Infection, lymphoma
Unrelated to HIV
Haematinic deficiencies 
Iron, vitamin B12, folate 
Pre-existing condition 
Sickle cell disease, renal failure
Unrelated to HIV
Haemolysis  
DIC, malaria, G6PD deficiency 
Blood loss
Hypersplenism 
Portal hypertension, low-grade NHL, myeloproliferative disorder
NHL = non-Hodgkin lymphoma; HL = Hodgkin lymphoma; TTP = thrombotic thrombocytopenic purpura; CMV = cytomegalovirus; DIC = disseminated intravascular coagulation; G6PD = 
glucose-6-phosphate dehydrogenase.
Table 2. Cytopenias caused by drug therapy
Drug Indication Cytopenias
Zidovudine (AZT) ARV: Reverse transcriptase inhibitor Anaemia, neutropenia
Stavudine (d4T) ARV: Reverse transcriptase inhibitor Neutropenia, thrombocytopenia
Ganciclovir CMV infection Neutropenia (40%), thrombocytopenia (20%), pancytopenia
Co-trimoxazole Pneumocystis, toxoplasmosis prophylaxis/treatment Megaloblastic anaemia, neutropenia, thrombocytopenia
Isoniazid
Rifampicin
Rifabutin
Tuberculosis and other mycobacteriae Anaemia, neutropenia, thrombocytopenia
Amphotericin B Antifungal Anaemia, leucopenia, thrombocytopenia
Fluconazole Antifungal Thrombocytopenia
ARV= antiretroviral; CMV= cytomegalovirus.
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advanced disease. Management includes HAART and prednisone at 
1 mg/kg/day if the platelet count is <30 x 109/l. If the platelet count 
does not improve after 2 weeks, referral to a tertiary haematology 
centre is advised. For patients unresponsive to initial doses of 
prednisone, the further management at our centre is to double the 
prednisone dose and if there is still no response, splenectomy is 
then considered. 
In our recent HIV bone marrow study, ITP was a frequent 
diagnosis, but the bone marrow findings did not add any further 
diagnostic information.5 This supports the argument that where the 
history, clinical examination and laboratory findings are compatible 
with the diagnosis of ITP, a bone marrow biopsy is unnecessary. 
Thrombotic thrombocytopenic 
purpura (TTP) 
TTP is a potentially lethal condition which occurs when ultra-large 
Von Willebrand factor (VWF) multimers cause platelet microthrombi 
in arterioles and capillaries. These platelet microthrombi lead to 
intravascular haemolysis and organ ischaemia. The red cells are 
mechanically sheared as they pass through the platelet thrombi in the 
microcirculation, leading to the characteristic red-cell fragments or 
‘schistocytes’ on the blood smear (Fig. 2). HIV is the most common 
virus precipitating TTP. Other precipitants include pregnancy, 
autoimmune disorders, malignancies and drugs, e.g. clopidogrel 
and statins.7 TTP is characterised by thrombocytopenia, micro-
angiopathic haemolytic anaemia (MAHA), fluctuating neurological 
signs, fever and renal impairment. In practice, however, not all 
features need to be present. British guidelines on the diagnosis 
and management of TTP8 state that severe thrombocytopenia plus 
significant red-cell fragmentation on the blood smear, and where other 
causes of MAHA, such as malignant hypertension and disseminated 
intravascular coagulation (DIC), have been excluded, is compatible 
with the diagnosis of TTP. Coagulation parameters are expected to 
be normal, in contrast to DIC, and the lactate dehydrogenase (LDH) 
is markedly elevated. Renal function should routinely be assessed 
and may be deranged; however, in acute severe renal impairment, an 
alternative diagnosis such as haemolytic uraemic syndrome should 
be considered. HIV-associated TTP typically occurs in young African 
females not on HAART and with high viral loads.9
In First World settings, the standard of care for HIV-associated 
TTP is plasma exchange in conjunction with steroids and HAART; 
however, plasmapharesis is not widely available in resource-poor 
settings. Our department showed that HIV-associated TTP is highly 
responsive to plasma infusion therapy;10 daily fresh-frozen plasma 
(FFP) infusions at 30 ml/kg/day in conjunction with prednisone 
1 mg/kg/day resulted in excellent response rates (95%). HAART 
should be simultaneously (re-)initiated.9 This protocol is feasible in 
cost-limited settings and has become the standard of care for HIV-
associated TTP in SA. FFP can be commenced at a local hospital, but 
all TTP patients should be referred to a tertiary centre for definitive 
management. The small proportion of TTP cases resistant to FFP 
then require plasmapharesis; other aetiologies such as underlying 
malignancy and autoimmune diseases should then be explored.
Lymphoma
HIV is associated with a markedly increased risk of malignancies, 
particularly high-grade B-cell lymphoma (Table 3). HIV infection 
increases NHL indicidence by 60 - 200-fold. The postulated mechanisms 
include chronic antigen stimulation, cytokine deregulation and Epstein-
Barr virus (EBV) and human herpes virus 8 (HHV8) co-infection. EBV 
has been identified in up to 40% of HIV-related lymphomas.11
Since the widespread introduction of HAART in SA in 2004, 
there has been an increase in HIV patients presenting at GSH with 
lymphoma with a particularly rapid increase in the incidence of 
Burkitt lymphoma/leukaemia (BL) (Professor N Novitzky, 2012 
unpublished observation) and diffuse large B-cell lymphoma.12 
BL is the most aggressive tumour known. In Burkitt lymphoma, 
the disease is localised to lymph nodes, while in Burkitt leukaemia, 
it is disseminated in the blood and bone marrow. BL is characterised 
by translocations of the c-MYC gene on chromosome 8 which lead 
to uncontrolled cell proliferation. Cytogenetic or fluorescent in situ 
hybridisation (FISH) analysis, available at tertiary centres in South 
Africa, usually reveals the characteristic translocation t(8;14). 
In HIV patients high-grade NHL typically presents with advanced 
clinical stage, bulky disease and a markedly elevated LDH. Many 
BL patients also present with, or develop, potentially lethal tumour 
lysis syndrome because of the very high cell turnover with associated 
simultaneous rapid cellular breakdown. Tumour lysis syndrome is 
characterised by hyperkalaemia, hyperuricaemia, hyperphosphataemia 
and renal dysfunction, and requires meticulous management including 
vigorous hydration, careful fluid balance, urinary alkalinisation and 
allopurinol. As a general principle, all HIV patients with lymphoma 
should receive HAART in conjunction with chemotherapy. 
Treatment for BL requires very intensive combination chemotherapy 
regimens with higher doses than those for acute leukaemias and 
other high-grade lymphomas. Because of the high incidence of BL 
Fig. 2. HIV-associated TTP: the blood smear is essential for diagnosis 
and typically shows marked thrombocytopenia, significant red-cell 
fragmentation (thick black arrows), polychromasia (large bluish-tinged 
red cells), microspherocytes (thin black arrows) and occasional nucleated 
red cells (dotted arrow). The coagulation parameters are normal and LDH 
is markedly increased.
Table 3. Malignancies in HIV
Non-Hodgkin lymphoma
Diffuse large B-cell lymphoma (DLBCL)
Plasmablastic lymphoma
Burkitt lymphoma/leukaemia 
Lymphoma arising in HHV8-associated multicentric Castleman 
disease
Primary effusion lymphoma
Hodgkin lymphoma
Myeloma
Kaposi sarcoma 
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patients at GSH, our bed capacity has been overwhelmed. A cost-
saving and bed-saving therapeutic strategy has thus been developed 
to allow BL patients to be effectively treated on a short, mainly 
outpatient protocol. This ultrashort dose-dense regimen (‘Cape 
Town regimen’) has shown considerable cost saving compared 
with standard protocols and comparable disease-free survival and 
treatment-related mortality,13 and may become a model for therapy 
in other centres confronting similar challenges. 
Another HIV-associated NHL occurring with increasing frequency 
at GSH is plasmablastic lymphoma (PL). This is an aggressive disease 
originally described in the oral cavity and associated with low CD4 
counts of <100 x 106/l. According to the World Health Organization 
(WHO), PL is rare.11 However, PL is not rare in our setting. A 
recent 4-year review at the GSH oncology department included 28 
patients with PL; 25 patients were HIV-positive and 3 patients HIV-
negative. The most common sites of involvement were the oral cavity, 
maxillary sinus and nasopharynx (32%) followed by bone (28%) and 
skin and subcutaneous lesions (20%). Although PL generally has a 
poor outcome, it responds to chemotherapy and radiotherapy with 
40% of patients in this study surviving for the 9-month follow-up 
period.14 
Other HHV8-associated malignancies occurring with increased 
frequency in HIV infection include large B-cell lymphoma arising in 
HHV8-associated multicentric Castleman disease, Kaposi sarcoma 
and primary effusion lymphoma.11 Primary effusion lymphoma is 
exceedingly rare in our centre with only one possible case in the last 
10 years (Dr Andrew McDonald, personal communication). However 
NHL arising in Castleman disease is not infrequent and classically 
presents with enlarging lymph nodes and massive splenomegaly. The 
disease responds well to standard cyclophosphamide, doxorubicin, 
vincristine, prednisolone (‘CHOP’) chemotherapy. 
HIV is known to be associated with a 5 - 10-fold increased 
incidence of HL, and in these patients there is a higher incidence 
of bone marrow involvement compared with HIV-negative patients 
(Fig. 3) (Table 3). HIV patients also have an increased incidence of 
primary bone marrow HL.15 Primary bone marrow HL, where there 
is no lymphadenopathy or organ involvement to suggest lymphoma, 
generally presents with cytopenias and ‘B symptoms’ (such as weight 
loss and night sweats) and has an aggressive clinical course. 
An adequate tissue biopsy sample is imperative for accurate 
histopathological diagnosis in lymphoma, and when the NHL is 
disseminated, blood/body fluid/bone marrow aspirate samples can 
be submitted for immunophenotyping by flow cytometric analysis, 
which greatly assists diagnosis.
Thrombosis
HIV is a prothrombotic condition associated with a 2 - 10-fold 
increased incidence of venous thromboembolism (VTE) compared 
with the HIV-negative population of the same age.16 The risk is highest 
with advanced disease and co-existing infections and malignancies. 
There is disruption of the normal balance of coagulation factors with 
an increase in prothrombotic proteins such as VWF and reduced 
natural anticoagulant proteins such as protein S and protein C. 
While most abnormal coagulation factors/markers improve after 
starting HAART, the disturbances fail to normalise completely.17 
HIV patients also have a higher incidence of the lupus anticoagulant 
and antiphospholipid antibodies than the general population, which 
may contribute to a hypercoagulable state. Therefore, clinicians 
should have a high index of suspicion for VTE in HIV patients and 
prophylactic anticoagulation should be considered for inpatients. 
Conclusions 
Haematological abnormalities in HIV are frequent and varied, with a 
wide clinical spectrum of disease. Usually multiple factors contribute 
to the haematological derangements, and a meticulous, logical 
approach, including consideration of all possible contributors such as 
haematinic deficiencies, drug effects and bone marrow infiltration, 
should be considered. Institution of HAART is a general rule of 
thumb and clinical management needs to be tailored to the particular 
complication. Life-threatening medical emergencies include TTP 
and tumour lysis syndrome in high-grade lymphoma; these require 
urgent hospitalisation and management.
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Fig. 3. Hodgkin lymphoma infiltration of the bone marrow. A Reed-Sternberg 
cell is highlighted by the black arrow. Malignant bone marrow infiltrations 
often present with cytopenias.
